Joseph A Sparano

List of Publications by Citations

Source: https://exaly.com/author-pdf/6717134/joseph-a-sparano-publications-by-citations.pdf
Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

273 papers	15,178 citations	59 h-index	120 g-index
295 ext. papers	18,599 ext. citations	6.4 avg, IF	6.26 L-index

#	Paper	IF	Citations
273	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. *New England Journal of Medicine*, **2018**, 379, 111-121	59.2	959
272	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. *New England Journal of Medicine*, **2015**, 373, 2005-14	59.2	865
271	Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. *Journal of Clinical Oncology*, **2014**, 32, 2959-66	2.2	780
270	Weekly paclitaxel in the adjuvant treatment of breast cancer. *New England Journal of Medicine*, **2008**, 358, 1663-71	59.2	701
269	Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. *Journal of Clinical Oncology*, **2007**, 25, 2127-32	2.2	566
268	Development of the 21-gene assay and its application in clinical practice and clinical trials. *Journal of Clinical Oncology*, **2008**, 26, 721-8	2.2	440
267	Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. *Lancet Oncology, The*, **2018**, 19, 27-39	21.7	413
266	A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. *Journal of the National Cancer Institute*, **2013**, 105, 701-10	9.7	353
265	Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. *Blood*, **2005**, 106, 1538-43	2.2	335
264	Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors. *Advances in Anatomic Pathology*, **2017**, 24, 311-335	5.1	299
263	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. *Advances in*	5.1	293
262	Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life. *Journal of Clinical Oncology*, **2007**, 25, 4387-95	2.2	281
261	Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. *Journal of Clinical Oncology*, **2008**, 26, 4063-71	2.2	271
260	Neoadjuvant chemotherapy induces breast cancer metastasis through a TMEM-mediated mechanism. *Science Translational Medicine*, **2017**, 9,	17.5	240
259	TAILORx: trial assigning individualized options for treatment (Rx). *Clinical Breast Cancer*, **2006**, 7, 347-50	3	217
258	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. *New England Journal of Medicine*, **2019**, 380, 2395-2405	59.2	208
257	Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. *Lancet Oncology, The*, **2018**, 19, 115-126	21.7	203

256	Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. *Blood*, **2010**, 115, 3008-16	2.2	202
255	Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. *Journal of Clinical Oncology*, **2007**, 25, 3415-20	2.2	197
254	Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. *Journal of Clinical Oncology*, **2008**, 26, 2473-81	2.2	190
253	Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. *Journal of Clinical Oncology*, **2010**, 28, 3256-63	2.2	181
252	Randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after first-line chemotherapy: Eastern Cooperative Oncology Group trial E2196. *Journal of Clinical Oncology*, **2004**, 22, 4683-90	2.2	174
251	Progress in adjuvant chemotherapy for breast cancer: an overview. *BMC Medicine*, **2015**, 13, 195	11.4	167
250	Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105. *Journal of Clinical Oncology*, **2015**, 33, 1895-901	2.2	166
249	Surgical Excision Without Radiation for Ductal Carcinoma in Situ of the Breast: 12-Year Results From the ECOG-ACRIN E5194 Study. *Journal of Clinical Oncology*, **2015**, 33, 3938-44	2.2	158
248	Dasatinib as a single agent in triple-negative breast cancer: results of an open-label phase 2 study. *Clinical Cancer Research*, **2011**, 17, 6905-13	12.9	154
247	Current Landscape of Immunotherapy in Breast Cancer: A Review. *JAMA Oncology*, **2019**, 5, 1205-1214	13.4	143
246	Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer. *Cancer*, **2012**, 118, 5937-46	6.4	138
245	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. *Lancet, The*, **2019**, 393, 1440-1452	40	137
244	Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer. *Journal of Clinical Oncology*, **2015**, 33, 2353-60	2.2	135
243	Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. *Cancer*, **2013**, 119, 1140-8	6.4	127
242	Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. *Journal of the National Cancer Institute*, **2014**, 106,	9.7	125
241	Targeting insulin inhibition as a metabolic therapy in advanced cancer: a pilot safety and feasibility dietary trial in 10 patients. *Nutrition*, **2012**, 28, 1028-35	4.8	123
240	Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. *Blood*, **2013**, 122, 3251-62	2.2	120
239	Seroconversion rates following COVID-19 vaccination among patients with cancer. *Cancer Cell*, **2021**, 39, 1081-1090.e2	24.3	104

238	Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. *Clinical Breast Cancer*, **2011**, 11, 306-11	3	102
237	Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma. *Cancer*, **2011**, 117, 336-42	6.4	102
236	Phase I trial of toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin's lymphoma. *Clinical Cancer Research*, **2007**, 13, 6168-74	12.9	102
235	Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494). *Journal of Clinical Oncology*, **2004**, 22, 1491-500	2.2	102
234	Association of Circulating Tumor Cells With Late Recurrence of Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncology*, **2018**, 4, 1700-1706	13.4	101
233	Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein. *Clinical Cancer Research*, **2015**, 21, 2359-66	12.9	95
232	Conducting Molecular Epidemiological Research in the Age of HIPAA: A Multi-Institutional Case-Control Study of Breast Cancer in African-American and European-American Women. *Journal of Oncology*, **2009**, 2009, 871250	4.5	95
231	Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. *Cancer*, **2010**, 116, 3969-77	6.4	94
230	Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. *Journal of Clinical Oncology*, **2018**, 36, 1556-1563	2.2	93
229	Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III study. *Journal of Clinical Oncology*, **2009**, 27, 1529-9	2.2	90
228	Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. *Journal of Clinical Oncology*, **2014**, 32, 3948-58	2.2	89
227	Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. *American Journal of Pathology*, **2006**, 168, 1998-2013	5.8	85
226	Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. *Journal of Clinical Oncology*, **2008**, 26, 4092-9	2.2	82
225	Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199. *Clinical Cancer Research*, **2015**, 21, 5082-5091	12.9	79
224	Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study. *Journal of Clinical Oncology*, **2019**, 37, 2206-2216	2.2	78
223	If we build it they will come: targeting the immune response to breast cancer. *Npj Breast Cancer*, **2019**, 5, 37	7.8	76
222	A phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer. *Clinical Cancer Research*, **2011**, 17, 6897-904	12.9	76
221	Immunophenotypic analysis of AIDS-related diffuse large B-cell lymphoma and clinical implications in patients from AIDS Malignancies Consortium clinical trials 010 and 034. *Journal of Clinical Oncology*, **2009**, 27, 5039-48	2.2	73

220	Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. *Journal of Clinical Oncology*, **2000**, 18, 2369-77	2.2	72
219	Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline - or -Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. *Clinical Cancer Research*, **2017**, 23, 4066-4076	12.9	69
218	Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer. *Journal of Clinical Oncology*, **2012**, 30, 3051-7	2.2	68
217	Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial. *Journal of the National Cancer Institute*, **2012**, 104, 406-14	9.7	65
216	Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. *Cancer*, **2012**, 118, 3977-83	6.4	61
215	Therapies for triple negative breast cancer. *Expert Opinion on Pharmacotherapy*, **2015**, 16, 983-98	4	60
214	HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families. *OncoImmunology*, **2015**, 4, e1026534	7.2	59
213	Phase II trial of tipifarnib plus neoadjuvant doxorubicin-cyclophosphamide in patients with clinical stage IIB-IIIC breast cancer. *Clinical Cancer Research*, **2009**, 15, 2942-8	12.9	59
212	A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer. *Clinical Cancer Research*, **2008**, 14, 6277-83	12.9	59
211	Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial. *JAMA Oncology*, **2020**, 6, 367-374	13.4	59
210	Targeted inhibition of farnesyltransferase in locally advanced breast cancer: a phase I and II trial of tipifarnib plus dose-dense doxorubicin and cyclophosphamide. *Journal of Clinical Oncology*, **2006**, 24, 3013-8	2.2	56
209	Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study. *Breast Cancer Research and Treatment*, **2012**, 134, 683-92	4.4	55
208	Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer. *Npj Breast Cancer*, **2020**, 6, 17	7.8	54
207	E2112: randomized phase iii trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. *Npj Breast Cancer*, **2018**, 4, 1	7.8	52
206	Eribulin mesylate versus ixabepilone in patients with metastatic breast cancer: a randomized Phase II study comparing the incidence of peripheral neuropathy. *Breast Cancer Research and Treatment*, **2013**, 140, 341-51	4.4	52
205	A common language in neoadjuvant breast cancer clinical trials: proposals for standard definitions and endpoints. *Lancet Oncology, The*, **2012**, 13, e240-8	21.7	51
204	Saquinavir enhances the mucosal toxicity of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma. *Medical Oncology and Tumor Pharmacotherapy*, **1998**, 15, 50-7		51
203	Cetuximab Plus Chemoradiotherapy in Immunocompetent Patients With Anal Carcinoma: A Phase II Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group Trial (E3205). *Journal of Clinical Oncology*, **2017**, 35, 718-726	2.2	49

202	Structure and cancer immunotherapy of the B7 family member B7x. *Cell Reports*, **2014**, 9, 1089-98	10.6	49
201	Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment. *Gynecologic Oncology*, **2010**, 119, 451-6	4.9	49
200	Cetuximab Plus Chemoradiotherapy for HIV-Associated Anal Carcinoma: A Phase II AIDS Malignancy Consortium Trial. *Journal of Clinical Oncology*, **2017**, 35, 727-733	2.2	47
199	Tumor infiltrating lymphocytes (TILs) improve prognosis in patients with triple negative breast cancer (TNBC). *OncoImmunology*, **2015**, 4, e985930	7.2	47
198	Colonic ischemia complicating immunotherapy with interleukin-2 and interferon-alpha. *Cancer*, **1991**, 68, 1538-44	6.4	47
197	Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial. *Clinical Cancer Research*, **2013**, 19, 1281-9	12.9	46
196	Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. *Clinical Cancer Research*, **2012**, 18, 2534-44	12.9	45
195	Genome-Wide Association Study for Anthracycline-Induced Congestive Heart Failure. *Clinical Cancer Research*, **2017**, 23, 43-51	12.9	44
194	Chemotherapy in Patients with Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer: An Overview. *Current Breast Cancer Reports*, **2013**, 5, 42-50	0.8	44
193	A phase I-II study of the histone deacetylase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer. *Breast Cancer Research and Treatment*, **2014**, 146, 145-52	4.4	41
192	Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer. *Surgical Oncology Clinics of North America*, **2017**, 26, 17-31	2.7	41
191	GRB7 is required for triple-negative breast cancer cell invasion and survival. *Breast Cancer Research and Treatment*, **2012**, 133, 607-15	4.4	40
190	Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. *Breast Cancer Research and Treatment*, **2014**, 144, 591-7	4.4	39
189	Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103). *Journal of Clinical Oncology*, **2018**, 36, 2621-2629	2.2	39
188	Clinical and Translational Results of a Phase II, Randomized Trial of an Anti-IGF-1R (Cixutumumab) in Women with Breast Cancer That Progressed on Endocrine Therapy. *Clinical Cancer Research*, **2016**, 22, 301-9	12.9	37
187	Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin lymphoma. *Cancer*, **1999**, 86, 1840-1847	6.4	37
186	A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. *Breast Cancer Research and Treatment*, **2010**, 119, 663-71	4.4	36
185	Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinoma. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2010**, 33, 121-4	2.7	35

184	Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer. *Journal of Clinical Oncology*, **1999**, 17, 880-6	2.2	34
183	Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103.. *Journal of Clinical Oncology*, **2014**, 32, 500-500	2.2	34
182	Human T cell leukemia virus reactivation with progression of adult T-cell leukemia-lymphoma. *PLoS ONE*, **2009**, 4, e4420	3.7	34
181	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. *Npj Breast Cancer*, **2019**, 5, 34	7.8	32
180	Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer. *Cancer Chemotherapy and Pharmacology*, **1994**, 34, 266-9	3.5	30
179	Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer. *Journal of Clinical Oncology*, **2021**, 39, 557-564	2.2	30
178	A new prognostic score for AIDS-related lymphomas in the rituximab-era. *Haematologica*, **2014**, 99, 1731-6	7.6	29
177	Ixabepilone-associated peripheral neuropathy: data from across the phase II and III clinical trials. *Supportive Care in Cancer*, **2012**, 20, 2661-8	3.9	29
176	ACCO: ASCO core curriculum outline. *Journal of Clinical Oncology*, **2005**, 23, 2049-77	2.2	29
175	Pathologic complete response (pCR) rates after neoadjuvant trastuzumab emtansine (T-DM1 [K]) + pertuzumab (P) vs docetaxel + carboplatin + trastuzumab + P (TCHP) treatment in patients with HER2-positive (HER2+) early breast cancer (EBC) (KRISTINE).. *Journal of Clinical Oncology*, **2016**, 34, 500-500	2.2	28
174	A metastasis biomarker (MetaSite Ⅱscore) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer. *Npj Breast Cancer*, **2017**, 3, 42	7.8	26
173	Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial. *Cancer Chemotherapy and Pharmacology*, **2011**, 68, 827-33	3.5	26
172	Charcot-Marie-Tooth gene, SBF2, associated with taxane-induced peripheral neuropathy in African Americans. *Oncotarget*, **2016**, 7, 82244-82253	3.3	26
171	High expression of class III Ⅱtubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer. *Clinical Breast Cancer*, **2013**, 13, 103-8	3	24
170	Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198. *Breast Cancer Research and Treatment*, **2010**, 121, 111-20	4.4	24
169	Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. *Journal of Clinical Oncology*, **2020**, 38, 1875-1886	2.2	23
168	Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. *Breast Cancer Research and Treatment*, **2011**, 125, 755-65	4.4	22
167	Phase I trial of metronomic oral vinorelbine in patients with advanced cancer. *Cancer Chemotherapy and Pharmacology*, **2011**, 68, 1119-24	3.5	22

166	Effects of Radiotherapy in Early-Stage, Low-Recurrence Risk, Hormone-Sensitive Breast Cancer. *Journal of the National Cancer Institute*, **2018**, 110, 1370-1379	9.7	22
165	Clinical studies examining the impact of obesity on breast cancer risk and prognosis. *Journal of Mammary Gland Biology and Neoplasia*, **2013**, 18, 257-66	2.4	21
164	Taxanes: impact on breast cancer therapy. *Anti-Cancer Drugs*, **2014**, 25, 512-21	2.4	21
163	Relationship between Topoisomerase 2A RNA Expression and Recurrence after Adjuvant Chemotherapy for Breast Cancer. *Clinical Cancer Research*, **2009**, 15, 7693-7700	12.9	21
162	Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer. *Cancer Chemotherapy and Pharmacology*, **2011**, 68, 379-88	3.5	19
161	Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial. *Npj Breast Cancer*, **2016**, 2, 16037	7.8	19
160	Randomized Phase III Postoperative Trial of Platinum-Based Chemotherapy Versus Capecitabine in Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy: ECOG-ACRIN EA1131. *Journal of Clinical Oncology*, **2021**, 39, 2539-2551	2.2	19
159	Plasmablastic lymphoma is treatable in the HAART era. A 10 year retrospective by the AIDS Malignancy Consortium. *Leukemia and Lymphoma*, **2016**, 57, 1731-4	1.9	18
158	A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103). *Breast Cancer Research and Treatment*, **2012**, 134, 345-52	4.4	18
157	Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer. *Clinical Cancer Research*, **2011**, 17, 7194-203	12.9	18
156	Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma. *Breast Cancer Research and Treatment*, **2013**, 141, 429-35	4.4	17
155	Clinical application of gene expression profiling in breast cancer. *Surgical Oncology Clinics of North America*, **2010**, 19, 581-606	2.7	17
154	HIV-associated lymphoma: the evidence for treating aggressively but with caution. *Current Opinion in Oncology*, **2007**, 19, 458-63	4.2	17
153	AIDS and non-AIDS diffuse large B-cell lymphomas express different antigen profiles. *Modern Pathology*, **2006**, 19, 438-46	9.8	17
152	Association of Magnetic Resonance Imaging and a 12-Gene Expression Assay With Breast Ductal Carcinoma In Situ Treatment. *JAMA Oncology*, **2019**, 5, 1036-1042	13.4	17
151	Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease. *Breast Cancer Research and Treatment*, **2013**, 138, 91-7	4.4	16
150	Human immunodeficiency virus associated lymphoma. *Current Opinion in Oncology*, **2003**, 15, 372-8	4.2	16
149	Vismodegib (V), a hedgehog (HH) pathway inhibitor, combined with FOLFOX for first-line therapy of patients (pts) with advanced gastric and gastroesophageal junction (GEJ) carcinoma: A New York Cancer Consortium led phase II randomized study.. *Journal of Clinical Oncology*, **2013**, 31, 4011-4011	2.2	16

148	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. *Journal of the National Cancer Institute*, **2021**, 113, 390-399	9.7	16
147	Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer. *Oncologist*, **2017**, 22, 245-254	5.7	15
146	A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). *Breast Cancer Research and Treatment*, **2017**, 165, 375-382	4.4	15
145	Complete remission in refractory anaplastic adult Wilms' tumor treated with cisplatin and etoposide. *Cancer*, **1991**, 67, 956-9	6.4	15
144	Enriched transcription factor signatures in triple negative breast cancer indicates possible targeted therapies with existing drugs. *Meta Gene*, **2015**, 4, 129-41	0.7	14
143	Phase II trials of cetuximab (CX) plus cisplatin (CDDP), 5-fluorouracil (5-FU) and radiation (RT) in immunocompetent (ECOG 3205) and HIV-positive (AMC045) patients with squamous cell carcinoma of the anal canal (SCAC): Safety and preliminary efficacy results.. *Journal of Clinical Oncology*, **2012**, [illegible]	2.2	14
142	Phase II trial of single agent PARP inhibitor ABT-888 (veliparib [vel]) followed by postprogression therapy of vel with carboplatin (carb) in patients (pts) with stage BRCA-associated metastatic breast cancer (MBC): California Cancer Consortium trial PHII-96.. *Journal of Clinical Oncology*, **2014**, 32, 1021-1021	2.2	14
141	Central nervous system involvement in AIDS-related lymphomas. *British Journal of Haematology*, **2016**, 173, 857-66	4.5	14
140	Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancer. *Cancer Investigation*, **2014**, 32, 439-44	2.1	13
139	Defining the clinical utility of gene expression assays in breast cancer: the intersection of science and art in clinical decision making. *Journal of Clinical Oncology*, **2010**, 28, 1625-7	2.2	13
138	A phase I trial of oblimersen sodium in combination with cisplatin and 5-fluorouracil in patients with advanced esophageal, gastroesophageal junction, and gastric carcinoma. *American Journal of Clinical Oncology: Cancer Clinical Trials*, **2010**, 33, 61-5	2.7	13
137	Risk of Recurrence and Mortality in a Multi-Ethnic Breast Cancer Population. *Journal of Racial and Ethnic Health Disparities*, **2017**, 4, 1181-1188	3.5	12
136	Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up. *Cancer Chemotherapy and Pharmacology*, **2020**, 85, 741-751	3.5	12
135	Impact of Genetic Ancestry on Outcomes in ECOG-ACRIN-E5103. *JCO Precision Oncology*, **2017**, 2017,	3.6	12
134	Phase I Trial of Veliparib, a Poly ADP Ribose Polymerase Inhibitor, Plus Metronomic Cyclophosphamide in Metastatic HER2-negative Breast Cancer. *Clinical Breast Cancer*, **2018**, 18, e135-e142	2	12
133	A 21-Gene Expression Assay in Breast Cancer. *New England Journal of Medicine*, **2016**, 374, 1387	59.2	12
132	Do community-based patient assistance programs affect the treatment and well-being of patients with breast cancer?. *Journal of Oncology Practice*, **2014**, 10, 48-54	3.1	11
131	Tenascin pattern of expression and established prognostic factors in invasive breast carcinoma. *Journal of Surgical Oncology*, **1998**, 68, 107-12	2.8	11

130	Clinical application of molecular profiling in breast cancer. *Future Oncology*, **2005**, 1, 485-96	3.6	11
129	Rhabdomyolysis: an unusual complication of cytotoxic chemotherapy. *Medical Oncology*, **1995**, 12, 219-23	3.7	11
128	The Contribution of Race to Breast Tumor Microenvironment Composition and Disease Progression. *Frontiers in Oncology*, **2020**, 10, 1022	5.3	10
127	Maintenance of clinical efficacy after dose reduction of ixabepilone plus capecitabine in patients with anthracycline- and taxane-resistant metastatic breast cancer: a retrospective analysis of pooled data from 2 phase III randomized clinical trials. *Clinical Breast Cancer*, **2012**, 12, 240-6	3	10
126	TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer. *Breast Cancer Research and Treatment*, **2012**, 134, 751-7	4.4	10
125	Comparative clinical benefits of systemic adjuvant therapy for paradigm solid tumors. *Cancer Treatment Reviews*, **2013**, 39, 27-43	14.4	10
124	Cerebral infection complicating systemic aspergillosis in acute leukemia: clinical and radiographic presentation. *Journal of Neuro-Oncology*, **1992**, 13, 91-100	4.8	10
123	Efficacy of the combination of ABT-888 (veliparib) and carboplatin in patients with BRCA-associated breast cancer.. *Journal of Clinical Oncology*, **2013**, 31, 1024-1024	2.2	10
122	Black race and distant recurrence after neoadjuvant or adjuvant chemotherapy in breast cancer. *Clinical and Experimental Metastasis*, **2018**, 35, 613-623	4.7	10
121	Predictive Value of Cytokines and Immune Activation Biomarkers in AIDS-Related Non-Hodgkin Lymphoma Treated with Rituximab plus Infusional EPOCH (AMC-034 trial). *Clinical Cancer Research*, **2016**, 22, 328-36	12.9	9
120	Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. *Breast Journal*, **2012**, 18, 303-11	1.2	9
119	The TAILORx trial: individualized options for treatment. *Community Oncology*, **2006**, 3, 494-496		9
118	Variable problems in lymphomas: CASE 3. Spontaneous regression of HIV-associated Burkitt's lymphoma of the cecum. *Journal of Clinical Oncology*, **2005**, 23, 8116-7	2.2	9
117	Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study.. *Journal of Clinical Oncology*, **2012**, 30, 1005-1005	2.2	9
116	Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034. *Leukemia and Lymphoma*, **2018**, 59, 1851-1860	1.9	9
115	E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor-Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. *Journal of Clinical Oncology*, **2021**, 39, 3171-3181	2.2	9
114	Clinical Trials for Treatment and Prevention of HIV-Associated Malignancies in Sub-Saharan Africa: Building Capacity and Overcoming Barriers. *JCO Global Oncology*, **2020**, 6, 1134-1146	3.7	8
113	Simulation Modeling of Cancer Clinical Trials: Application to Omitting Radiotherapy in Low-risk Breast Cancer. *Journal of the National Cancer Institute*, **2018**, 110, 1360-1369	9.7	8

112	Carbohydrate restriction in patients with advanced cancer: a protocol to assess safety and feasibility with an accompanying hypothesis. *Community Oncology*, **2008**, 5, 22-26		8
111	Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).. *Journal of Clinical Oncology*, **2015**, 33, 520-520	2.2	8
110	Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). *Clinical Lymphoma, Myeloma and Leukemia*, **2018**, 18, 180-190.e2	2	7
109	Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach. *Investigational New Drugs*, **2014**, 32, 542-8	4.3	7
108	Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer. *Journal of Geriatric Oncology*, **2013**, 4, 346-52	3.6	7
107	High Expression of FGD3, a Putative Regulator of Cell Morphology and Motility, Is Prognostic of Favorable Outcome in Multiple Cancers. *JCO Precision Oncology*, **2017**, 1,	3.6	7
106	Chronic thalidomide and chemoembolization for hepatocellular carcinoma. *Oncologist*, **2014**, 19, 1229-30	5.7	7
105	Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. *Clinical Colorectal Cancer*, **2010**, 9, 290-6	3.8	7
104	Plasma matrix metalloproteinases 7 and 9 in patients with metastatic breast cancer treated with marimastat or placebo: Eastern Cooperative Oncology Group trial E2196. *Clinical Breast Cancer*, **2006**, 6, 525-9	3	7
103	TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.. *Journal of Clinical Oncology*, **2018**, 36, LBA1-LBA1	2.2	7
102	Surveillance After Treatment of Localized Breast Cancer: Time for Reappraisal?. *Journal of the National Cancer Institute*, **2019**, 111, 339-341	9.7	7
101	Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. *Clinical Breast Cancer*, **2019**, 19, 268-277.e1	3	6
100	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. *JNCI Cancer Spectrum*, **2019**, 3, pkz050	4.6	6
99	Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma. *Advances in Hematology*, **2012**, 2012, 403648	1.5	6
98	Translating Genomic Research into Clinical Practice: Promise and Pitfalls. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2013**, 33, 15-23	7.1	6
97	New agents for the management of resistant metastatic breast cancer. *Expert Opinion on Pharmacotherapy*, **2017**, 18, 1815-1831	4	5
96	How do I treat inflammatory breast cancer?. *Current Treatment Options in Oncology*, **2013**, 14, 66-74	5.4	5
95	Reply to K. Dunleavy et al. *Journal of Clinical Oncology*, **2010**, 28, e261-e262	2.2	5

94	A phase I trial of gemcitabine administered as a 96-h continuous intravenous infusion in patients with advanced carcinoma and lymphoma. *Medical Oncology*, **2006**, 23, 369-76	3.7	5
93	Disseminated aspergillosis after fungemia in a patient with extragonadal germ cell tumor undergoing autologous bone marrow transplantation. *Cancer*, **1991**, 68, 1842-4	6.4	5
92	ABT-888 (veliparib) in combination with carboplatin in patients with stage IV BRCA-associated breast cancer. A California Cancer Consortium Trial.. *Journal of Clinical Oncology*, **2012**, 30, 1010-1010	2.2	5
91	10-year update of E2197: Phase III doxorubicin/docetaxel (AT) versus doxorubicin/cyclophosphamide (AC) adjuvant treatment of LN+ and high-risk LN- breast cancer and the comparison of the prognostic utility of the 21-gene recurrence score (RS) with clinicopathologic features.. *Journal of Clinical Oncology*, **2012**, 30, 1021-1021	2.2	5
90	Macrocytosis and dysplastic anemia is associated with the cyclin-dependent kinase 4/6 inhibitor palbociclib in metastatic breast cancer. *Haematologica*, **2018**, 103, e98-e102	6.6	5
89	Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas. *Blood Advances*, **2018**, 2, 3618-3626	7.8	5
88	TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps. *Journal of Clinical Oncology*, **2019**, 37, 1841-1842	2.2	4
87	Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker Study. *Oncologist*, **2020**, 25, e1158-e1169	5.7	4
86	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. *JNCI Cancer Spectrum*, **2019**, 3, pkz049	4.6	4
85	Farnesyl transferase inhibitors. *Cancer Investigation*, **2008**, 26, 653-61	2.1	4
84	First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.. *Journal of Clinical Oncology*, **2017**, 35, 1047-1047	2.2	4
83	AMC 095 (AIDS Malignancy Consortium): A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV associated solid tumors (ST) with expansion cohorts in HIV associated solid tumors and classical Hodgkin lymphoma (cHL).. *Journal of Clinical Oncology*, **2018**, 36, TPS2597-TPS2597	2.2	4
82	Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study.. *Journal of Clinical Oncology*, **2019**, 37, 500-500	2.2	4
81	Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108).. *Journal of Clinical Oncology*, **2022**, JCO2102006	2.2	4
80	Translating genomic research into clinical practice: promise and pitfalls. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2013**, 15-23	7.1	4
79	Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial. *Cancer*, **2021**, 127, 2545-2552	6.4	4
78	Response-adapted therapy with infusional EPOCH chemotherapy plus rituximab in HIV-associated, B-cell non-Hodgkin's lymphoma. *Haematologica*, **2021**, 106, 730-735	6.6	4
77	Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer. *Npj Breast Cancer*, **2021**, 7, 20	7.8	4

76	Preoperative Breast MRI for Newly Diagnosed Ductal Carcinoma in Situ: Imaging Features and Performance in a Multicenter Setting (ECOG-ACRIN E4112 Trial). *Radiology*, **2021**, 301, 66-77	20.5	4
75	Evaluation of serum Amphiregulin levels in breast cancer patients and cancer-free controls. *Experimental Hematology and Oncology*, **2013**, 2, 25	7.8	3
74	The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis.. *Npj Breast Cancer*, **2022**, 8, 4	7.8	3
73	Presurgical evaluation of the AKT inhibitor MK-2206 in patients with operable invasive breast cancer.. *Journal of Clinical Oncology*, **2014**, 32, 2613-2613	2.2	3
72	Phase II trials of cetuximab plus combined modality therapy (CMT) in squamous cell carcinoma of the anal canal (SCCAC) with and without human immunodeficiency virus (HIV) infection.. *Journal of Clinical Oncology*, **2016**, 34, 3522-3522	2.2	3
71	Refined estimates of local recurrence risks and the impact of the DCIS score adjusting for clinico-pathological features: Meta-analysis of E5194 and Ontario DCIS cohort studies.. *Journal of Clinical Oncology*, **2017**, 35, 528-528	2.2	3
70	A phase I/II dose escalation and expansion study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in combination with fulvestrant in subjects with ER+ breast cancer.. *Journal of Clinical Oncology*, **2017**, 35, TPS1114-TPS1114	2.2	3
69	Deconstructing Racial and Ethnic Disparities in Breast Cancer. *JAMA Oncology*, **2021**, 7, 355-356	13.4	3
68	Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions. *Journal of Clinical Oncology*, **2021**, 39, 2893-2902	2.2	3
67	Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. *JNCI Cancer Spectrum*, **2019**, 3, pkz062	4.6	2
66	Validation of an Automated Quantitative Digital Pathology Approach for Scoring TMEM, a Prognostic Biomarker for Metastasis. *Cancers*, **2020**, 12,	6.6	2
65	Recommendations for research priorities in breast cancer by the coalition of cancer cooperative groups scientific leadership council: imaging and local therapy. *Breast Cancer Research and Treatment*, **2010**, 120, 273-84	4.4	2
64	Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma. *Medical Oncology*, **2005**, 22, 257-67	3.7	2
63	Genomic and Pathway Connectivity Analyses Identify Novel Strategies to Overcome mTOR Inhibitor Resistance In DLBCL. *Blood*, **2010**, 116, 436-436	2.2	2
62	AMC-053: Pilot Study of an Oncolytic Viral Strategy Using Bortezomib with ICE +/- Rituximab for Relapsed/Refractory HIV+ Lymphomas. *Blood*, **2016**, 128, 786-786	2.2	2
61	A multicenter phase II study of bevacizumab (B) and temsirolimus (T) in women with recurrent epithelial ovarian cancer (OC): A study of the Mayo, Chicago, California, New York, Southeast, and Princess Margaret Phase II Consortia.. *Journal of Clinical Oncology*, **2013**, 31, 5517-5517	2.2	2
60	A phase II prospective trial correlating progression-free survival (PFS) with CYP2D6 activity in patients with metastatic breast cancer treated with tamoxifen: ECOG-ACRIN E3108.. *Journal of Clinical Oncology*, **2016**, 34, 546-546	2.2	2
59	A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.. *Journal of Clinical Oncology*, **2017**, 35, TPS1112-TPS1112	2.2	2

58	The AKT inhibitor triciribine in combination with paclitaxel has order-specific efficacy against Zfp217-induced breast cancer chemoresistance. *Oncotarget*, **2017**, 8, 108534-108547	3.3	2
57	Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer. *Expert Opinion on Pharmacotherapy*, **2021**, 22, 981-1003	4	2
56	Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2 positive breast cancer. *Breast Cancer Research and Treatment*, **2021**, 189, 177-185	4.4	2
55	The clinical utility of gene expression assays in breast cancer patients with 0-3 involved lymph nodes. *Therapeutic Advances in Medical Oncology*, **2021**, 13, 17588359211038467	5.4	2
54	Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy: A Post Hoc Analysis of a Randomized Clinical Trial. *JAMA Oncology*, **2021**,	13.4	2
53	Tenascin pattern of expression and established prognostic factors in invasive breast carcinoma **1998**, 68, 107		2
52	Reply to T. Grenader et al. *Journal of Clinical Oncology*, **2010**, 28, e195-e196	2.2	1
51	Reply to J.M. Guinebretiere and L. Arnould et al. *Journal of Clinical Oncology*, **2009**, 27, 2734-2735	2.2	1
50	Targeting Epigenetic Modifications for the Treatment and Prevention of Breast Cancer. *Current Breast Cancer Reports*, **2010**, 2, 198-207	0.8	1
49	Is there a role for ovarian function suppression in operable breast cancer?. *Breast Cancer Research and Treatment*, **2010**, 123, 311-3	4.4	1
48	Immunological Therapy of Breast Cancer. *BioDrugs*, **1994**, 1, 135-147		1
47	Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer.. *Npj Breast Cancer*, **2022**, 8, 16	7.8	1
46	Genome wide association study for anthracycline-induced congestive heart failure.. *Journal of Clinical Oncology*, **2016**, 34, 1017-1017	2.2	1
45	Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.. *Journal of Clinical Oncology*, **2016**, 34, 1074-1074	2.2	1
44	Prospective study of magnetic resonance imaging (MRI) and multiparameter gene expression assay in ductal carcinoma in situ (DCIS): A trial of the ECOG-ACRIN Cancer Research Group (E4112).. *Journal of Clinical Oncology*, **2017**, 35, 534-534	2.2	1
43	AMC075: A randomized phase II trial of vorinostat with R-EPOCH in aggressive HIV-related NHL.. *Journal of Clinical Oncology*, **2018**, 36, 7573-7573	2.2	1
42	Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient-reported outcomes substudy. *Cancer*, **2021**,	6.4	1
41	Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study. *BMJ Open*, **2021**, 11, e053397	3	1

40	AIDS malignancy consortium (AMC) 095: A phase I study of ipilimumab (IPI) and nivolumab (NIVO) in advanced HIV-associated solid tumors (ST) with expansion cohorts in HIV-associated solid tumors and classical Hodgkin lymphoma (cHL).. *Journal of Clinical Oncology*, **2018**, 36, TPS44-TPS44	2.2	1
39	Phase II trial of echinomycin in patients with advanced or recurrent colorectal cancer **1994**, 34, 266		1
38	Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.. *Journal of Clinical Oncology*, **2014**, 32, 36-36	2.2	1
37	RE: Advanced Breast Cancer Definitions by Staging System Examined in the Breast Cancer Surveillance Consortium. *Journal of the National Cancer Institute*, **2021**, 113, 938-939	9.7	1
36	Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. *Journal of the National Cancer Institute*, **2021**,	9.7	1
35	Techniques and Thresholds for Quantifying Circulating Tumor Cells in Breast Cancer-In Reply. *JAMA Oncology*, **2019**, 5, 574	13.4	1
34	Reply to T. Shimoi et al and Y. Shimanuki et al. *Journal of Clinical Oncology*, **2021**, 39, 3522-3524	2.2	1
33	Patterns of central nervous system recurrence in patients with systemic human immunodeficiency virus-associated non-Hodgkin lymphoma **1999**, 86, 1840		1
32	Breast cancer patients who are obese at diagnosis: alea iacta est? or "is the die cast"?. *Oncology*, **2011**, 25, 1002, 1004, 1007	1.8	1
31	A pooled analysis of 1,144 patients with HIV-associated lymphoma: Assessment of lymphoma-, HIV-, and treatment-specific factors on clinical outcomes.. *Journal of Clinical Oncology*, **2012**, 30, 8005-8005	2.2	0
30	Patient-Reported Testing Burden of Breast Magnetic Resonance Imaging Among Women With Ductal Carcinoma In Situ: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112). *JAMA Network Open*, **2021**, 4, e2129697	10.4	0
29	Tolerability of bevacizumab and chemotherapy in a phase 3 clinical trial with human epidermal growth factor receptor 2-negative breast cancer: A trajectory analysis of adverse events. *Cancer*, **2021**, 127, 4546-4556	6.4	0
28	Phase I-II study of the histone deacetytase inhibitor vorinostat plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in locally advanced breast cancer.. *Journal of Clinical Oncology*, **2014**, 32, 598-598	2.2	0
27	Phase Ib study of rebastinib plus antitubulin therapy with paclitaxel or eribulin in patients with metastatic breast cancer (MBC).. *Journal of Clinical Oncology*, **2017**, 35, TPS2611-TPS2611	2.2	0
26	Randomized Phase II Trial of Capecitabine and Lapatinib with or without IMC-A12 (Cituxumumab) in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab and Chemotherapy: NCCTG N0733 (Alliance). *Breast Cancer Research and Treatment*, **2021**, 188, 477-487	4.4	0
25	Immune Activation and Microbial Translocation as Prognostic Biomarkers for AIDS-Related Non-Hodgkin Lymphoma in the AMC-034 Study. *Clinical Cancer Research*, **2021**, 27, 4642-4651	12.9	0
24	Association Between Surgery Preference and Receipt in Ductal Carcinoma In Situ After Breast Magnetic Resonance Imaging: An Ancillary Study of the ECOG-ACRIN Cancer Research Group (E4112).. *JAMA Network Open*, **2022**, 5, e2210331	10.4	0
23	Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer-Reply. *JAMA Oncology*, **2020**, 6, 586	13.4	

22	Taxane chemotherapy treatment for metastatic breast cancer. *Breast Cancer Management*, **2013**, 2, 507-517	5.7
21	Reply to T.J. Smith et al. *Journal of Clinical Oncology*, **2010**, 28, e129-e130	2.2
20	Systemic therapy for triple-negative breast cancer: A changing landscape.. *Critical Reviews in Oncology/Hematology*, **2022**, 171, 103608	7
19	Long-term outcomes in women with low-risk hormone-sensitive early-stage breast cancer.. *Journal of Clinical Oncology*, **2018**, 36, e12583-e12583	2.2
18	Simulation modeling of the effects of adjuvant chemotherapy in early-stage breast cancer.. *Journal of Clinical Oncology*, **2019**, 37, 526-526	2.2
17	CNS involvement in patients with AIDS-related lymphomas.. *Journal of Clinical Oncology*, **2014**, 32, 8570-8570	2.2
16	Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.. *Journal of Clinical Oncology*, **2015**, 33, 533-533	2.2
15	Tumor Infiltrating Lymphocytes as a Prognostic and Predictive Biomarker in Breast Cancer **2016**, 167-186	
14	The Tumor Microenvironment as a Metastasis Biomarker in Breast Cancer **2016**, 153-165	
13	Suppression of poly-ADP ribose (PAR) levels in PBMCs by veliparib (vel) as a pharmacodynamic (PD) marker associated with survival among women with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).. *Journal of Clinical Oncology*, **2016**, 34, 2549-2549	2.2
12	Association of Charcot-Marie-Tooth gene, SBF2, with taxane-induced peripheral neuropathy in African Americans.. *Journal of Clinical Oncology*, **2016**, 34, 1026-1026	2.2
11	Long-Term Follow-up of Rituximab and Infusional Cyclophosphamide, Doxorubicin, and Etoposide (cde) in Combination with HAART in HIVRelated Non-Hodgkin Lymphomas (NHL).. *Blood*, **2008**, 112, 1467-1467	2.2
10	Targeting EGFR in HPV-Associated Cancer **2010**, 211-234	
9	Long-Term Follow-up of Rituximab and Infusional Cyclophosphamide, Doxorubicin, and Etoposide (CDE) In Combination with HAART In HIV-Related Non-Hodgkin's Lymphomas (NHL). *Blood*, **2010**, 116, 5072-5072	2.2
8	Comparison of the incidence of peripheral neuropathy (PN) with eribulin versus ixabepilone (IXA) in metastatic breast cancer (MBC) patients: A randomized phase II study.. *Journal of Clinical Oncology*, **2012**, 30, 121-121	2.2
7	Biomarker prediction of chemotherapy-related amenorrhea.. *Journal of Clinical Oncology*, **2013**, 31, 9508-9508	2.2
6	A phase I-II study of tipifarnib plus weekly paclitaxel (P) followed by dose-dense doxorubicin/cyclophosphamide (AC) in stage IIb-IIIc breast cancer (BC).. *Journal of Clinical Oncology*, **2013**, 31, 1118-1118	2.2
5	Reply to K. Ando et al. *Journal of Clinical Oncology*, **2021**, 39, 1947-1948	2.2

4	Reply to C. Shah et al. *Journal of Clinical Oncology*, **2016**, 34, 1824-5	2.2
3	In Regard to Bruner et al. *International Journal of Radiation Oncology Biology Physics*, **2016**, 94, 1220-1	4
2	Abstract P4-10-02: Patient-reported outcomes in EA1131: A randomized phase III trial of platinum vs. capecitabine in patients with residual triple-negative breast cancer after neoadjuvant chemotherapy. *Cancer Research*, **2022**, 82, P4-10-02-P4-10-02	10.1
1	Abstract PD9-01: Expanding downstaging criteria in AJCC pathologic prognostic staging using OncotypeDx Recurrence Score assay in T1-2N0 hormone-receptor positive patients enrolled in the TAILORx trial. *Cancer Research*, **2022**, 82, PD9-01-PD9-01	10.1